PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
439.10%
Positive EBIT growth while AGEN is negative. John Neff might see a substantial edge in operational management.
10.94%
Positive operating income growth while AGEN is negative. John Neff might view this as a competitive edge in operations.
11.95%
Net income growth under 50% of AGEN's 57.67%. Michael Burry would suspect the firm is falling well behind a key competitor.
11.92%
EPS growth under 50% of AGEN's 62.86%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
11.92%
Diluted EPS growth under 50% of AGEN's 62.86%. Michael Burry would worry about an eroding competitive position or excessive dilution.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
61.50%
Similar OCF growth to AGEN's 65.11%. Walter Schloss would assume comparable operations or industry factors.
61.50%
FCF growth similar to AGEN's 65.13%. Walter Schloss would attribute it to parallel capital spending and operational models.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-26.75%
Negative 10Y OCF/share CAGR while AGEN stands at 94.71%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-26.75%
Negative 5Y OCF/share CAGR while AGEN is at 95.74%. Joel Greenblatt would question the firm’s operational model or cost structure.
-12.80%
Negative 3Y OCF/share CAGR while AGEN stands at 88.47%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-1.77%
Negative 10Y net income/share CAGR while AGEN is at 98.30%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-1.77%
Negative 5Y net income/share CAGR while AGEN is 94.49%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-83.78%
Negative 3Y CAGR while AGEN is 84.00%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-414.12%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-414.12%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-184.96%
Negative 3Y equity/share growth while AGEN is at 84.56%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.90%
We have a declining book value while AGEN shows 48.52%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
-100.00%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
No Data
No Data available this quarter, please select a different quarter.
-7.50%
We cut SG&A while AGEN invests at 20.19%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.